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Alzheimer’s disease genetics and ABCA7 splicing
Jared B. Vasquez, James F. Simpson, Ryan Harpole, and Steven Estus*
Department of Physiology and Sanders-Brown Center on Aging, University of Kentucky, 800 S. 
Limestone St., Rm. 330, Lexington, KY 40536
Abstract
Both common and rare polymorphisms within ABCA7 have been associated with Alzheimer’s 
disease (AD). In particular, the rare AD associated polymorphism rs200538373 was associated 
with altered ABCA7 exon 41 splicing and an AD risk odds ratio of ~1.9. To probe the role of this 
polymorphism in ABCA7 splicing, we used minigene studies and qPCR of human brain RNA. We 
report aberrant ABCA7 exon 41 splicing in the brain of a carrier of the rs200538373 minor C 
allele. Moreover, minigene studies show that rs200538373 acts as a robust functional variant in 
vitro. Lastly, although the ABCA7 isoform with an extended exon 41 is predicted to undergo 
nonsense mediated RNA decay, this was not supported by qPCR analyses, which showed 
relatively normal ABCA7 mRNA levels in the carrier of the rs200538373 minor C allele. In 
summary, rs200538373 is a functional polymorphism that alters ABCA7 exon 41 splicing without 
grossly altering the level of ABCA7 mRNA.
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Introduction
AD currently affects as many as 5.1 million people in the United States [1]. As ‘baby 
boomers’ age, AD prevalence is projected to triple by the year 2050 unless a treatment is 
found [1]. Since pharmacologic agents based on genetic mechanisms are more likely to 
successfully transition to drugs approved by the Food and Drug Administration [2], we seek 
to elucidate the actions underlying AD-associated SNPs.
Single nucleotide polymorphisms (SNP)s in ABCA7 were identified as AD risk factors in 
several studies [3–6]. These SNPs included several common SNPs that were associated with 
modest AD risk, including rs3764650, rs4147914, rs3752246, and rs4147929 [3–5]. These 
SNPs were also found to associate with ABCA7 expression, cortical and hippocampal 
atrophy, as well as β-secretase activity in cells expressing the amyloid-β protein precursor 
(AβPP)-Swedish mutation [3, 7–9]. In addition to these common ABCA7 SNPs, several rare 
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ABCA7 SNPs, including rs200538373, were associated with AD at odds ratios as high as 
1.9 [6].
The role of ABCA7 function itself in AD is unclear. Recent findings using human brain 
show ABCA7 is expressed at low levels in several cell types, including neurons and 
microglia [10]. ABCA7 has been implicated in lipid transport, phagocytosis and Aβ 
homeostasis [11–17].
Here, we sought to better understand the role of the rare SNP, rs200538373, which was 
associated with ABCA7 exon 41 splicing in blood [6]. We extend these prior findings by 
reporting an aberrant 14 bp extension of exon 41 in the brain of an individual that was 
heterozygous for this SNP. The hypothesis that this SNP is functional was supported by in 
silico modeling and by an ABCA7 minigene study, which demonstrated that rs200538373 
acts to alter exon 41 splicing. Lastly, ABCA7 expression in a carrier of the minor allele of 
rs200538373 was similar to that of other brain samples; this finding is inconsistent with 
hypothesized nonsense mediated RNA decay for this isoform, suggesting that the likely 
action for this SNP is altered splicing leading to a truncated ABCA7 protein.
Materials and Methods
Ethics statement
This work was conducted under the approval of the University of Kentucky Institutional 
Review Board.
Human brain tissue
RNA was purified from human anterior cingulate brain samples (supplied by the University 
of Kentucky AD Center Neuropathology Core) and converted to cDNA as previously 
described [18–20]. The AD status of the brain donors was determined by the AD Center 
Neuropathology and Clinical Cores by using guidelines that included evaluation of 
neurofibrillary tangles and neuritic senile plaques as well as cognitive status [21–23]. Age at 
death for the cognitively intact, i.e. non-AD donors, was 82.6 ± 1.6 (mean ± SE, n = 28) 
while AD donors were 81.7 ± 1.2 (mean ± SE, n = 28). The post-mortem interval (PMI) for 
non-AD and AD donors was 2.7 ± 0.2 (n = 28) hours and 3.4 ± 0.1 (n = 28), respectively.
Genotyping
DNA samples were genotyped for the indicated polymorphisms by using FAM and VIC dye-
labeled probes (Invitrogen, Carlsbad, CA) and TaqMan polymerase chain reaction (PCR) 
(Bio-Rad, Hercules, CA).
Splicing assay
ABCA7 exon 41 splicing was assessed by PCR coupled to polyacrylamide gel 
electrophoresis (PAGE). Reactions contained a sense primer corresponding to sequence 
within exon 40, i.e., 5′-CCGTGGGCAGAGGATG-3′ and an antisense primer 
corresponding to exon 42 sequence, i.e., 5′-TCGGATTGAGGGCAGTATC-3′. Each 20 μL 
reaction mixture contained ~20 ng of cDNA, 25 pmole of each primer, and Platinum Taq 
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(ThermoFisher) and was subjected to a PCR profile of 30 cycles at 95°C for 15 s, 59°C for 
30 s, and 72°C for 20 s. PCR products were separated on 10% polyacrylamide gels and 
detected by SYBR gold fluorescence (ThermoFisher) as per manufacturer’s protocol. Each 
sample was analyzed twice and reactions lacking cDNA template were analyzed in parallel 
to check for PCR product contamination.
Maximum entropy scores
The sequences of the ABCA7 exon 41 isoforms were scored for 5′ splice site favorability 
by using an online prediction tool ((http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq_acc.html [24]. Briefly, this algorithm was trained on large datasets 
of human splice sites to calculate a log odds ratio for a splicing score for input sequence 
[24]. A higher score correlates with a more favorable splice site [24, 25].
RNA splicing assay
ABCA7 minigenes for each rs200538373 allele were generated by PCR and contained exon 
41, intron 41, and exon 42 in their entirety, cloned into pcDNA3.1 (ThermoFisher). 
Minigene construction used a sense primer corresponding to sequence at the start of exon 
41, i.e., 5′-TGTTTTGGGCTGCTGG-3′ and an antisense primer corresponding to sequence 
at the end of exon 42, i.e., 5′-CTGGGCAACCTGGGC-3′. Sequencing confirmed inserts 
were accurate and complete for each allele and differed only for rs200538373 alleles. 
Human Be(2)-M17 neuroblastoma cells (ATCC, Manassas, VA) were maintained in Opti-
MEM I reduced-serum medium supplemented to 10% fetal bovine serum, 50 U/ml penicillin 
and 50 μg/ml streptomycin with humidified 5% carbon dioxide at 37°C. For transfections, 
cells (1×106) were plated in 350 μL media in a 24-well plate, allowed to grow 24 hrs and 
then transfected in triplicate by using 2 μg of allele-specific ABCA7 minigene vector and 
Lipofectamine 3000, as per manufacturer’s protocol (ThermoFisher). Forty-eight hours after 
transfection, RNA was prepared and reverse transcribed using random hexamers and 
Superscript III as described previously [26]. ABCA7 expression from each minigene was 
detected by PCR using a pcDNA3.1 vector-derived forward primer (5′-
ACTAGTCCAGTGTGGTGGAATTGCC-3′) and exon 42-derived reverse primer (5′-
TCGGATTGAGGGCAGTATC-3′).
Quantitative PCR assay
The quantification of ABCA7, synaptophysin, ITGAM and AIF1 expression in these 
samples has been described previously [7, 26, 27]. Briefly, 20 μL reactions contained 1μM 
of each primer, 1x PerfeCTa SYBR Green Super Mix (Quanta Biosciences), and 
approximately 20 ng cDNA generated from anterior cingulate RNA. PCR was conducted 
using an initial 2-minute incubation at 95°, followed by cycles of 10 seconds at 95°, 20 
seconds at 60°, and 20 seconds at 72°. Experimental samples were amplified in parallel with 
serially diluted standards that were generated by PCR of cDNA followed by purification and 
quantitation by UV absorbance. Results from samples were compared relative to the 
standard curve to calculate copy number in each sample. Real time assays were performed 
twice and the average copy number was used for further analyses.
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Statistical Analysis
ABCA7 expression was analyzed by linear regression (SPSS, version 23). Each model 
included AD status and rs3764650 genotype. In addition, since ABCA7 is expressed in both 
microglia and neurons [16, 17], we included expression of either (i) a neuronal gene 
(synaptophysin), (ii) microglial genes (geometric mean of ITGAM and AIF1), or (iii) both 
the neuronal and microglial genes (SPSS, v. 23). The geometric mean of ITGAM and AIF1 
was used, as opposed to the arithmetic mean, because AIF1 levels were markedly higher 
than ITGAM levels. To generate a normal distribution of the data, the square root of the 
copy number data was used for the linear regression analyses; the square root approach was 
validated by the Shapiro-Wilk test for normality. We also analyzed the expression results for 
variation in sample mRNA content by dividing mRNA copy number by the geometric mean 
of two constitutively expressed genes, i.e., RPL32 and EIF4H [26]. To generate a normal 
distribution as assessed by Shapiro-Wilk, regression analyses used the square root of these 
values. Since our cohort of samples had only one rs3764650 minor allele homozygous 
individual, we used a dominant model for this analysis, i.e., rs3764650 minor allele carriers 
were considered as a single group.
Results
Rs200538373 is a rare intronic ABCA7 variant that was associated with AD risk and with 
exon 41 splicing in blood [6]. To confirm and extend this finding, we determined 
rs200538373 genotypes in a set of 57 cDNA samples generated from AD and non-AD 
brains; this effort identified a single sample that was heterozygous for rs200538373 (G/C) 
while the remainder were major allele (G/G) homozygous. The frequency of the 
rs200538373 minor C allele in our cohort was 0.8%, similar to that reported previously in 
European datasets [6, 28].
To explore the effects of the C allele of rs200538373, we sought to confirm whether aberrant 
splicing occurs in the brain of an individual with this allele. To assess splicing, cDNA from 
the rs200538373 heterozygous sample as well as several rs200538373 major allele 
homozygous samples was subjected to RT-PCR with amplicons spanning exon 40 to exon 42 
(Figure 1A). We observed the expected product along with an additional longer amplicon for 
the sample that was heterozygous for rs200538373 (Figure 1B). Sanger sequencing of this 
longer amplicon found that exon 41 was extended 14 bp into the typical intron 41. 
Interestingly, the sequence electropherogram shows the rs200538373 minor C allele but not 
the major G allele (Figure 1C). Although not quantitative, this suggests that this abnormal 
splice form is largely produced from the minor allele of the ABCA7 pre-mRNA. The 14 bp 
inclusion would encode an in-frame UGA termination codon beginning at position 2 in the 
extension and is therefore predicted to produce a truncated ABCA7 protein.
To test directly whether rs200538373 modulates exon 41 splicing, we generated minigenes 
for each ABCA7 allele. The constructs included all of exon 41, intron 41, and exon 42 
(Figure 2A). Since ABCA7 is expressed in neurons, as well as other brain cell types [10, 29, 
30], we tested the minigene splicing in the human neural cell line Be(2)-M17. We found that 
the transcript from the minigene with the rs200538373 minor C allele was spliced to 
generate exon 41 with the 14 bp extension (Figure 2B). Conversely, the minigene with the 
Vasquez et al. Page 4
J Alzheimers Dis. Author manuscript; available in PMC 2018 April 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
rs200538373 major G allele was spliced to generate exon 41 at the usual 5′ consensus splice 
site. The effect of the SNP in this assay was very robust, with minimal “normal” isoform 
generated by the minigene carrying the minor C allele and minimal extended isoform 
generated by the minigene carrying the major G allele.
To gain further insight into this finding, we used MaxEntScan::score5ss, a 5′ splice site 
prediction tool, to compare the normal 5′ consensus splice site in the presence of each 
rs200538373 allele and the aberrant splice site. We observe that the favorable score of the 
major G allele for rs200538373 at the normal splice site is reduced when the minor C allele 
of rs200538373 is present (Table 1). The aberrant splice site 14 bp further into the intron is 
unaffected by the SNP and has a splicing score that is competitive with the normal splice site 
when the G allele of rs200538373 is present. These results are consistent with rs200538373 
being a functional SNP resulting in the normal 5′ consensus splice site being used when the 
G allele of rs200538373 is present and the aberrant splice site 14 bp further into the intron 
being used when minor C allele of rs200538373 is present.
Lastly, we assessed indirectly whether the aberrant splicing and predicted premature 
termination codon observed with the minor C allele of rs200538373 may be associated with 
nonsense mediated RNA decay by comparing ABCA7 expression in rs200538373 major G 
allele homozygous individuals with that of the single rs200538373 heterozygous individual 
in our cohort of samples. For this effort, we established a quantitative model of ABCA7 
expression.. This model included ABCA7 expression as well as AD status and rs3764650, a 
common AD-associated ABCA7 SNP [3–5]. ABCA7 expression was assessed previously by 
qPCR using primers in the constitutively spliced exons 44 and 45 [7] and those data are re-
analyzed here. Since ABCA7 is expressed in neurons and microglia, we compared models 
that evaluated ABCA7 expression relative to expression of microglial and neuronal genes 
separately and together (Table 2). The ABCA7 expression model that used only the neuronal 
mRNA synaptophysin had slightly more explanatory power (Figure 3A, adjusted R2=0.700) 
than a model that included synapthophysin as well as microglial (ITGAM and AIF1) 
mRNAs (adjusted R2=0.697). A model that used only the microglial mRNAs had a lower 
goodness-of-fit (adjusted R2=0.323). Within each model, ABCA7 expression was increased 
significantly in AD individuals and decreased significantly in carriers of the minor 
rs3764650 allele (Table 2, Figure 3A). We also analyzed these data by normalizing mRNA 
copy numbers to two “housekeeping” mRNAs (Figure 3B). Although this model is less 
visually striking (adjusted R2 of 0.412), ABCA7 expression was significantly increased in 
AD (standardized β coefficient=0.559, p=3.0×10−6) and the minor allele of rs3764650 was 
associated with a significant decrease in ABCA7 expression (standardized β coefficient=
−0.383, p=0.001). ABCA7 expression in the individual that was heterozygous for 
rs200538373 was similar to that of other samples (Figure 3A–B, arrow). Hence, the 
individual with the minor C allele of rs200538373 did not have a large decrease in ABCA7 
expression, a finding we interpret as suggesting that nonsense mediated RNA decay does not 
grossly affect ABCA7 expression. In summary, this quantitative analysis of ABCA7 
expression suggests that (i) the minor AD-protective allele of rs3764650 is associated with 
decreased ABCA7 expression, (ii) AD itself is associated with increased ABCA7 
expression, and (iii) the rare AD-associated SNP rs200538373 acts through altered splicing 
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without grossly affecting ABCA7 expression levels, a finding supported by another quite 
recent study [31].
Discussion
The primary findings of this report are that abnormal ABCA7 exon 41 splicing is found in 
the brain of an individual carrying the minor C allele of rs200538373 and that rs200538373 
is a functional SNP. Additional findings include that rs200538373 does not appear 
associated with a gross decline in ABCA7 expression, suggesting that NMD does not 
grossly impact ABCA7 expression for this individual, and a confirmation that ABCA7 
expression is decreased with the minor allele of rs3764650 and increased in AD. As such, 
this report confirms and extends a report that rs200538373 was associated with ABCA7 
exon 41 splicing in blood [6] and our prior report that AD and rs3764650 was associated 
with expression per se [7].
The mechanisms underlying AD genetic risk factors are currently under intense 
investigation. Common ABCA7 SNPs such as rs3764650 have been associated with a 
modest increase in AD risk (odds ratio: 1.23) while rare SNPs that involve premature stop 
termination codons, such as rs200538373, are associated with increased AD risk (odds ratio: 
1.91) [4, 6, 32, 33]. In our original report examining rs3764650, we found that the minor 
allele of rs3764650 was associated with a decrease in ABCA7 expression with a 
standardized beta-coefficient of −0.375 [7]. Here, we re-analyzed these ABCA7 data by 
using a model that incorporated levels of mRNAs specific to microglia and neurons. This 
analysis produced a similar result, with the rs3764650 minor allele being associated with 
reduced ABCA7 expression. Hence, modestly reduced ABCA7 expression correlates with a 
modest increase in the AD odds ratio. In contrast, the rare rs200538373 was associated with 
aberrant exon 41 splicing that was predicted to produce a premature translation termination 
codon [6]. In pursuing the effect of this SNP, we observed a very robust SNP effect on exon 
41 splicing in vitro and that the extended exon 41 isoform was clearly present in the brain of 
the rs200538373 minor allele carrier. That noted, the in vivo finding was limited because we 
identified only a single sample with the SNP minor allele. An additional limitation of this 
study was that we were unable to identify isoform specific qPCR primers and hence were 
not able to quantify the extended exon 41 splice variant. Our semi-quantitative gel-based 
analysis suggested that this extended exon 41 isoform was present at a level approaching that 
of the normal ABCA7 isoform. Hence, the effect of the SNP may approach 50% of ABCA7 
mRNA containing a premature stop codon. This truncated ABCA7 protein would likely 
represent a loss of function because the encoded ABCA7 protein would lack its second 
ATPase domain. This effect could be greater if the truncated ABCA7 acts as a dominant 
negative; this possibility is supported by reports that similarly truncated ABCA1 proteins act 
as a dominant negative in dimer formation with full-length ABCA1 [34–36]. In summary, 
we interpret these results overall as showing that rs3764650, a common SNP associated with 
a modest reduction in ABCA7 expression, leads to a small increase in AD risk. The increase 
in ABCA7 observed in AD may represent a compensatory attempt to increase ABCA7 and 
thereby reduce AD risk or may reflect other inflammation related processes. In contrast, 
rs200538373, a rare SNP associated with a more robust reduction in ABCA7, leads to a 
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larger increase in AD risk. Overall, these results appear to essentially demonstrate a genetic 
dose response between functional impact and AD risk.
Considering the translational impact of these findings, agents that increase ABCA7 
expression would be expected to reduce AD risk, especially for those individuals with the 
minor allele of rs3764650. Since ABCA7 expression is increased in AD, we speculate that a 
pharmacologic intervention to reduce AD risk would likely have to begin well before disease 
onset. With regards to rs200538373 and ABCA7 splicing, we note that in this age of 
personalized medicine, several drugs that target splicing are in human trials or have been 
approved for human use. Some of these agents involve peripheral tissue, such as eteplirsen 
which targets splicing in a form of Duchene muscular dystrophy [37]. However, other agents 
target splicing in the central nervous system, with the drug nusinersen, which was recently 
FDA approved [38] for spinal muscular atrophy, being the most robust representative [39]. 
As science moves forward, agents that target aberrant splicing for AD may emerge.
In summary, our primary finding is an apparent dose response between the functional impact 
of AD-associated SNPs and AD risk. This finding is based upon (i) the observation that 
rs200538373, which is associated with robust AD risk, appears to have a robust effect on 
splicing in vitro with aberrant splicing found in the brain of a minor allele carrier and (ii) the 
observation that rs3764650, which is associated with modest AD risk, is associated with a 
modest reduction in ABCA7 expression.
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Figure 1. 
Aberrant ABCA7 exon 41 splicing in an rs200538373 heterozygous sample. A). RNA 
purified from the brains of a rs200538373G/C individual and several rs200538373G/G 
individuals was reverse transcribed and subjected to PCR with primers corresponding to 
sequences within exons 40 and 42. The amplicon size for normal splicing was 222 bp. B). 
The expected splice product as well as a longer ABCA7 isoform was consistently detected 
only in the rs200538373G/C individual (denoted by *). C). Sanger sequencing of the longer 
ABCA7 isoform found that exon 41 was extended by 14 bp relative to the expected isoform. 
This sequence from the rs200538373 heterozygous individual includes the last two bp of 
exon 41, the 14 bp extension of exon 41, and the first two bp of exon 42. Only the 
rs200538373 minor C allele is observed (marked by asterisk) (blue=C, black=G, green=A, 
red=T).
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Figure 2. 
Rs200538373 is a functional SNP that modulates ABCA7 exon 41 splicing. A). Cells were 
transfected in triplicate with constructs that expressed ABCA7 exon 41, intron 41, and exon 
42 and that carried with the rs200538373 major G or minor C allele. These transcripts also 
included vector-derived 5′ and 3′ sequence. B). RT-PCR analyses with a forward primer 
targeting vector sequence and a reverse primer targeting exon 42 detect normal splicing (192 
bp amplicon) from the major G allele minigene and aberrant splicing (206 bp amplicon) in 
the minor C allele minigene. Note that ‘C’ and ‘G’ labels indicate rs200538373 alleles while 
‘NC’ labels a negative control sample wherein cells were transfected in parallel with an 
irrelevant (GFP) gene. This result was replicated in three independent experiments.
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Figure 3. 
ABCA7 expression is associated with AD status and rs3764650 but appears unaffected by 
rs200538373. A). When ABCA7 expression was analyzed by comparing ABAC7 mRNA 
copy numbers relative to a neuronal mRNA, expression appeared to correlate with 
rs3764650 and AD status. For both A and B, the arrow points to the single sample that was 
heterozygous for rs200538373. Additionally, rs3764650T refers to rs3764650T/T 
homozygous samples while rs3764650G refers to rs3764650G/T heterozygous samples as 
well as a single rs3764650G/G homozygous sample. B). ABCA7 expression relative to AD 
status and rs3764650 when mRNA copy numbers were normalized to RPL32 and EIF4H 
housekeeping mRNAs. For both A and B, the square root of values was used to generate a 
normal distribution of the data.
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Table 1
Impact of rs200538373 on ABCA7 exon 41 splicing. This SNP is at position 5, in parenthesis, within intron 
41 and is predicted to weaken the splice site, i.e., the prototypic splice donor sequence is CAG/gtragt (exon in 
upper case, intron in lower case, r = purine).
Exon 41 Splicing Splice Site Sequence (splice site at ^) Splicing Score
Normal Splice Site
Major G allele
CAG^gtga(g)g 10.07
Normal Splice Site
Minor C allele
CAG^gtga(c)gggtgccaggtaggg 7.66
Aberrant Splice Site
Extended Exon 41
CAGgtga(g/c)gggtgccag^gtaggg 9.46
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